|
|
|
||
(State of incorporation)
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
The
|
Exhibit
Number
|
Description
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
Date: September 22, 2023
|
ACELRX PHARMACEUTICALS, INC.
|
||
By:
|
/s/ Raffi Asadorian
|
||
Raffi Asadorian
|
|||
Chief Financial Officer
|
Document And Entity Information |
Sep. 22, 2023 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | ACELRX PHARMACEUTICALS, INC. |
Document, Type | 8-K |
Document, Period End Date | Sep. 22, 2023 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-35068 |
Entity, Tax Identification Number | 41-2193603 |
Entity, Address, Address Line One | 1850 Gateway Drive, Suite 175 |
Entity, Address, City or Town | San Mateo |
Entity, Address, State or Province | CA |
Entity, Address, Postal Zip Code | 94404 |
City Area Code | 650 |
Local Phone Number | 216-3500 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | ACRX |
Security Exchange Name | NASDAQ |
Entity, Emerging Growth Company | false |
Amendment Flag | false |
Entity, Central Index Key | 0001427925 |
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end
2]FWHODKY%>
M'+M10];M47Q84;\Z)_C!FW;,@9>8X=N>$OV3FSNR EJ"3_J;<]*];P&CLMW"
M_>*47#_324;9/:2T'V?;WS>G<176P/WB_)C[+6Y MDT%M,
MEO*$)':%) 5@9>QD5 #&W_R(22RY/#W_>K:RBNR?=T<3F0"^;)UV"I]ZG=;G
M0NMDT.G5"?6NZ5PEL8"YYI-!ID$FS*S*QBPCSB220(T,(50 N8Q\MY!MPFLO
M*R3X[7@]"9".#R; X*+]!>^0WD:"NZ2(W!"C/-%?\D2!+HSB^U7I"U>Q#!GN
MKR[FV +4@&$;:ZI-6"?WM+.7 3,6"V$#5'*-:9X
M)EI)T0=M/X9\0F<\YB2:,<_&H';:17(*05.B)1$07:+6H)'-D[F($C.& J@#
M1B1'A SQN!&O9.QMHI .)2 .B=!K^2)])@XK+8&K PO_%AOP WGX)"<]U#GI
MDN7]E,4 GG=F$S[D2,37E*4^7N!AU\RQ8G=WN=0?]QS$4UWT)/&=DZ0XI"I0"@1;SF*]I^7T6N.8T\]UG!&Z[OA-S8^L+/$_ B$&.AWS="ND +Y]=Z]ENOO[B*RF-,VJEEU]((,>$,3UV)@K3/;#